Benefits of Glucosamine HCl for Dogs – Gut-Joint Axis Support

Glucosamine – Joint and Mobility Support for Dogs

Summary

Glucosamine hydrochloride (HCl) is an amino sugar that serves as a fundamental building block for glycosaminoglycans (GAGs) and proteoglycans — the structural molecules that give articular cartilage its compressive resistance and resilience. In osteoarthritis, the balance between cartilage synthesis and degradation shifts toward net loss, and exogenous glucosamine provides the substrate needed to support repair.¹ A randomised, double-blind canine clinical trial demonstrated that dogs receiving oral glucosamine HCl with chondroitin sulphate showed statistically significant improvements in pain, weight-bearing, and overall clinical condition by day 70 (p < 0.001), with effects comparable to carprofen.¹ Beyond its structural role, glucosamine inhibits NF-κB-mediated inflammatory signalling in chondrocytes, suppressing COX-2 expression and prostaglandin E2 production.² Emerging research also reveals that orally administered glucosamine modulates the gut microbiome — altering bacterial community composition and improving gastrointestinal symptoms — establishing a connection between this joint-support compound and gut health.³ Bonza includes glucosamine HCl across three products: at 300 mg/kg in Superfoods & Ancient Grains complete food, at 240mg per chewy in Bounce Bioactive Bites, and as part of a 254.93mg glucosamine complex per chewy in Boost Bioactive Bites.

Key Takeaways

• Glucosamine HCl provides the essential amino sugar substrate for the biosynthesis of glycosaminoglycans and proteoglycans, the structural molecules responsible for cartilage compressive resistance and joint fluid viscosity.⁴
• In a randomised, double-blind canine clinical trial, dogs receiving oral glucosamine HCl and chondroitin sulphate demonstrated statistically significant improvements in pain, weight-bearing, and clinical severity by day 70 (p < 0.001), with efficacy comparable to the NSAID carprofen.¹
• Glucosamine inhibits NF-κB activation in osteoarthritic chondrocytes in a dose-dependent manner, reducing COX-2 expression, prostaglandin E2 production, and the activity of matrix-degrading enzymes (MMPs), through a mechanism that includes epigenetic modulation of inflammatory gene promoters.²˒⁵
• A pharmacokinetic study in beagle dogs established that oral glucosamine HCl has approximately 12% bioavailability with rapid absorption (Tmax 1.5 hours), confirming that orally administered glucosamine reaches systemic circulation and joint tissues.⁶
• A randomised, double-blind, placebo-controlled crossover trial demonstrated that glucosamine supplementation significantly modulates gut microbial composition — altering nine bacterial genera including Lachnospiraceae — and reduces gastrointestinal symptoms including bloating, establishing a link between this joint-support compound and the gut-joint axis.³˒⁷

In this guide:

• What Is Glucosamine HCl?
• Bioactive Compounds and How They Work
• Health Benefits for Dogs
• Glucosamine HCl and Gut Health
• Why Bonza Includes Glucosamine HCl
• Safety Profile
• How to Give Glucosamine HCl to Your Dog
• Dosage Guidelines
• Practical Considerations
• Frequently Asked Questions
• Related Reading
• References
• Editorial Information
• About the Author

What Is Glucosamine HCl?

Glucosamine (2-amino-2-deoxy-D-glucose) is a naturally occurring amino sugar found in virtually all connective tissues in the mammalian body. It is the most abundant monosaccharide used in the biosynthesis of glycosaminoglycans (GAGs) — the long, unbranched polysaccharide chains that, together with core proteins, form the proteoglycans responsible for the structural integrity and compressive resistance of articular cartilage.⁴

In a healthy joint, chondrocytes continuously synthesise glucosamine from glucose and glutamine via the hexosamine biosynthetic pathway.⁴ This endogenous production fuels the assembly of key GAGs including hyaluronic acid, chondroitin sulphate, keratan sulphate, and heparan sulphate — all of which are essential for maintaining cartilage hydration, synovial fluid viscosity, and the shock-absorbing properties of the joint. As osteoarthritis progresses, the demand for GAG synthesis exceeds the chondrocyte’s capacity to produce glucosamine at a rate sufficient to keep pace with degradation, contributing to the progressive thinning and deterioration of the cartilage matrix.

Glucosamine is commercially available in several salt forms: glucosamine hydrochloride (HCl), glucosamine sulphate (often stabilised with sodium chloride or potassium chloride), and N-acetyl-D-glucosamine. Glucosamine HCl provides the highest concentration of free glucosamine per gram — approximately 83% by weight compared to approximately 65% for glucosamine sulphate — because the hydrochloride salt has a lower molecular weight than the sulphate salt complexes.⁴ This is why glucosamine HCl is the predominant form used in veterinary joint-support products.⁴ Regardless of the salt form, all glucosamine salts dissociate in the acidic environment of the stomach, releasing free glucosamine for absorption.⁴

The therapeutic use of glucosamine dates back to the 1960s in Europe, where it was originally used in human medicine for osteoarthritis management. Its application in veterinary medicine has since become widespread, with glucosamine-containing products now among the most commonly recommended supplements for dogs with joint conditions.⁴

Bioactive Compounds and How They Work

Unlike multi-compound botanical supplements, glucosamine HCl delivers a single bioactive molecule — free glucosamine — that exerts its effects through multiple complementary mechanisms.

Glycosaminoglycan Substrate Provision

Glucosamine’s most fundamental role is as a biosynthetic precursor. Once absorbed, free glucosamine enters the hexosamine biosynthetic pathway and is converted to UDP-N-acetylglucosamine, which serves as the essential donor molecule for the synthesis of glycosaminoglycans.⁴ These GAGs — particularly chondroitin sulphate and hyaluronic acid — form the hydrated gel that gives cartilage its compressive strength and articular surfaces their smooth, low-friction properties. By providing an exogenous supply of this rate-limiting substrate, glucosamine supplementation may support the chondrocyte’s capacity to maintain and repair the cartilage extracellular matrix.

NF-κB Pathway Inhibition

Beyond its structural role, glucosamine is a potent inhibitor of the NF-κB inflammatory signalling pathway in chondrocytes. Largo et al. (2003) demonstrated in human osteoarthritic chondrocytes that glucosamine inhibits IL-1β-induced NF-κB activation in a dose-dependent manner, blocking the nuclear translocation of p50 and p65 NF-κB subunits and increasing cytoplasmic IκBα — the protein that sequesters NF-κB in its inactive form.² This suppression of NF-κB resulted in significantly reduced COX-2 expression and prostaglandin E2 (PGE2) production, two key mediators of joint inflammation and pain.²

Imagawa et al. (2011) extended these findings by demonstrating that glucosamine’s anti-inflammatory effects include an epigenetic component: glucosamine prevents cytokine-induced demethylation of a specific CpG site in the IL-1β promoter in human chondrocytes, thereby reducing aberrant IL-1β expression associated with the degradative OA phenotype.⁵ This epigenetic mechanism suggests glucosamine may help maintain the normal, non-degradative phenotype of chondrocytes exposed to inflammatory stimuli.

Matrix Metalloproteinase Suppression

The NF-κB-dependent anti-inflammatory activity of glucosamine extends to the suppression of matrix metalloproteinases (MMPs) — the enzymes directly responsible for cartilage matrix degradation in osteoarthritis. Glucosamine and chondroitin sulphate in combination suppress IL-1-induced gene expression of MMP-13 and aggrecanases (ADAMTS-5) in cartilage explants, while simultaneously upregulating TIMP-3 (tissue inhibitor of metalloproteinases-3), a potent endogenous inhibitor of these catabolic enzymes.⁹ Glucosamine alone has been shown to inhibit MMP-2 and MMP-9 expression via downregulation of the NF-κB pathway.⁹

Broad-Spectrum Chondroprotection

Transcriptomic analysis using whole-genome microarrays has revealed that glucosamine acts as a broad-spectrum inhibitor of IL-1β-mediated gene activation in chondrocytes.¹⁰ When chondrocytes are pre-treated with glucosamine and then challenged with IL-1β, the inflammatory cytokine’s ability to upregulate catabolic genes — including chemokines, inflammatory mediators, and matrix-degrading enzymes — is substantially attenuated across hundreds of gene targets.¹⁰ This global protective effect suggests glucosamine functions not as a targeted anti-inflammatory but as a comprehensive chondroprotective agent that preserves the normal metabolic state of the chondrocyte.

Health Benefits for Dogs

Pain Reduction and Improved Weight-Bearing

The most clinically relevant evidence for glucosamine in dogs comes from McCarthy et al. (2007), who conducted a randomised, double-blind, positive-controlled, multi-centre trial in 35 dogs with confirmed osteoarthritis of the hips or elbows.¹ Dogs received either oral glucosamine HCl with chondroitin sulphate or carprofen (the positive control NSAID) for 70 days, followed by a 28-day washout period. The glucosamine group demonstrated statistically significant improvements in veterinarian-assessed scores for pain on palpation, weight-bearing, and overall clinical condition by day 70 (p < 0.001).¹ Onset of significant improvement was slower than for carprofen-treated dogs — reflecting the gradual, substrate-dependent mechanism of action — but glucosamine was judged non-inferior to carprofen at the day 70 assessment.¹

Anti-Inflammatory Effects in Vivo

A randomised, placebo-controlled, double-blind trial by Collaresi et al. (2022) evaluated a multi-ingredient supplement containing glucosamine, chondroitin sulphate, hyaluronic acid, Boswellia serrata, and green tea extract in 40 dogs with osteoarthritis over 60 days.¹¹ Dogs receiving the active supplement demonstrated significantly improved veterinary orthopaedic scores and owner-assessed chronic pain index scores compared to placebo. Complete blood analysis confirmed no adverse effects on haematological or biochemical parameters over the treatment period.¹¹ While this study used a multi-ingredient formulation, the glucosamine component contributed to the established chondroprotective and anti-inflammatory profile of the combination.

Cartilage Protection in Experimental Models

In a canine model of surgically induced osteoarthritis, Canapp et al. (1999) demonstrated that dogs receiving glucosamine HCl and chondroitin sulphate for 21 days prior to induced synovitis showed reduced lameness and protective effects against chemically induced synovitis and associated bone remodelling, as evaluated by scintigraphic assessment.⁴ Separately, Wenz et al. (2017) demonstrated in a randomised, placebo-controlled study using the cruciate-deficient canine model that orally administered glucosamine sulphate at 200 mg/kg body weight for 8 weeks produced significantly reduced histological OA changes compared to placebo, with protective effects observed in both articular cartilage and subchondral bone.⁸

Evidence in Context

It is important to present the evidence honestly: clinical trials of glucosamine in dogs have produced mixed results. Moreau et al. (2003) found no significant improvement over placebo in a randomised trial, and a 2023 study by Kampa et al. using force-plate analysis found that glucosamine/chondroitin did not produce significant improvements in peak vertical force over 6 weeks.⁴˒¹² However, as Bhathal et al. (2017) note in their systematic review, the variation in study outcomes likely reflects differences in glucosamine dosing, product quality, treatment duration, and outcome measures — many studies used treatment periods shorter than the 8–10 weeks typically required for measurable structural effects.⁴ The overall body of evidence supports glucosamine as a slow-acting, well-tolerated supplement that may provide cumulative benefits when used as part of a multi-modal joint-support strategy rather than as a standalone fast-acting treatment.

Glucosamine HCl and Gut Health

One of the most significant recent developments in glucosamine research is the recognition that this joint-support compound interacts extensively with the gut microbiome — directly reinforcing the gut-joint axis.

Gut Microbiome Modulation

Only approximately 10–12% of orally administered glucosamine HCl is absorbed from the gastrointestinal tract.⁶ The unabsorbed fraction — representing the majority of each oral dose — reaches the colon, where it is utilised by gut bacteria.³ This means glucosamine is not simply a joint supplement that passes through the gut; it is an active substrate for microbial metabolism.

Navarro et al. (2019) conducted a randomised, double-blind, placebo-controlled crossover trial in healthy adults and found that 14 days of glucosamine and chondroitin supplementation significantly modulated nine bacterial genera compared to placebo (FDR < 0.05).⁷ Abundances of four Lachnospiraceae genera and two Prevotellaceae genera were increased, while Bifidobacterium and a member of the Christensenellaceae family were decreased.⁷ The authors concluded that interindividual variation in gut microbial composition may help explain the well-documented heterogeneity in therapeutic responses to glucosamine.⁷

Functional Gut Health Benefits

Moon et al. (2021) conducted a randomised, double-blind, placebo-controlled crossover study specifically evaluating non-shellfish-derived glucosamine HCl on gut health markers.³ Three weeks of supplementation significantly reduced stomach bloating compared to placebo, with trends toward reduced constipation and hard stools.³ Phylogenetic diversity and proportions of specific bacterial families — Pseudomonadaceae, Peptococcaceae, and Bacillaceae — were significantly reduced following glucosamine consumption.³ Notably, no glucosamine was detected in any faecal samples, indicating complete utilisation by the gut microbiota before reaching the colon’s distal segments.³

The Gut-Joint Axis Connection

Shmagel et al. (2019) conducted a systematic review of evidence from animal and human studies on the effects of glucosamine and chondroitin on gut microbial composition, concluding that these supplements are predominantly utilised by gut microbiota and that gut bacteria consume more than 50% of orally administered glucosamine before it can be absorbed.⁶˒¹³ Critically, the absorbed fraction varies with antibiotic use, suggesting that the state of the gut microbiome directly influences glucosamine bioavailability to the host.¹³

This has a direct practical implication: the efficacy of oral glucosamine supplementation may be partly determined by the health of the gut microbiome. Zhu et al. (2021) demonstrated in a murine model that glucosamine reversed gut microbial imbalances induced by a high-fat diet, inhibited inflammatory responses in colon tissue, and reduced NF-κB signalling — establishing a mechanistic link between glucosamine’s gut-level activity and systemic anti-inflammatory effects.¹⁴ These findings position glucosamine not merely as a cartilage substrate but as a compound with genuine gut-organ axis activity.

For a comprehensive overview of how gut health influences joint inflammation and mobility in dogs, see our dedicated article: The Gut-Joint Axis: How Your Dog’s Gut Health Affects Their Joints.

Why Bonza Includes Glucosamine HCl

Glucosamine HCl is one of the most widely included ingredients across Bonza’s product range — present in Superfoods & Ancient Grains complete food (300 mg/kg), Bounce Bioactive Bites (240mg per chewy), and Boost Bioactive Bites (182mg glucosamine HCl plus 72.93mg N-acetyl-D-glucosamine per chewy) — because it addresses the most fundamental requirement of joint health: providing the raw building material from which cartilage is constructed and maintained.

The choice of the hydrochloride salt over glucosamine sulphate is deliberate. Glucosamine HCl delivers approximately 83% free glucosamine by weight compared to roughly 65% for the sulphate form, meaning more active compound reaches the dog per milligram of ingredient.⁴ It is also more chemically stable, with no requirement for sodium chloride or potassium chloride stabiliser salts — avoiding unnecessary dietary sodium and simplifying formulation.⁴ Both salt forms dissociate in the stomach to release identical free glucosamine, so the therapeutic molecule is the same; the difference lies in delivery efficiency and formulation integrity.⁴ Equally important, Bonza sources its glucosamine HCl from fungal fermentation rather than shellfish chitin, ensuring full compatibility with a plant-based formulation while delivering a chemically identical compound.

In Bounce, glucosamine HCl at 240mg per chewy forms the cornerstone of a comprehensive joint-support formulation. While glucosamine provides the structural substrate for cartilage repair, chondroitin sulphate (80mg) inhibits degradative enzymes, hyaluronic acid (5mg) restores synovial fluid lubrication, MSM (120mg) provides bioavailable sulphur for connective tissue, and ASU (10mg) stimulates chondrocyte collagen production. Anti-inflammatory botanicals including curcumin, Boswellia, and rosehip address the inflammatory cascade through complementary pathways. The inclusion of KynoSil (15mg; a complex of glucosamine, MSM, and bioavailable silicon) provides additional joint-support compounds, including silicon — a trace element involved in collagen cross-linking and connective tissue integrity.

The gut health dimension is equally intentional. Given that the majority of oral glucosamine is metabolised by gut bacteria, and that microbial composition influences glucosamine bioavailability, Bounce includes prebiotic FOS (80mg) and β-glucans (83mg Biolex MB40) to support the microbial environment in which glucosamine is processed. This reflects Bonza’s “One Gut. Whole Dog.” philosophy — the recognition that even a traditional joint-support ingredient like glucosamine is intimately connected to gut health.

In Boost, the glucosamine complex (254.93mg total) combines glucosamine HCl with N-acetyl-D-glucosamine, providing two complementary forms that may support broader GAG synthesis. Boost also includes Calsporin (Bacillus velezensis, 75mg) and Lactobacillus helveticus (5mg) — direct probiotic support that further reinforces the gut microbiome’s role in glucosamine metabolism and joint health.

In Superfoods & Ancient Grains, glucosamine HCl at 300 mg/kg provides daily baseline joint support as part of a complete food — meaning dogs receiving Bonza’s complete food are already consuming glucosamine at a maintenance level before any supplement is added.

Safety Profile

Glucosamine HCl has an excellent safety record across decades of use in both veterinary and human medicine. As an amino sugar naturally produced by every mammalian body, exogenous glucosamine is well tolerated and non-toxic at supplement-level doses.

In the McCarthy et al. (2007) canine clinical trial, no adverse effects attributable to glucosamine/chondroitin supplementation were reported during the 70-day treatment period or the subsequent 28-day washout.¹ The Collaresi et al. (2022) trial similarly reported no side effects and confirmed normal haematological and biochemical parameters throughout the 60-day study.¹¹

A commonly raised concern is whether glucosamine supplementation affects blood glucose regulation, given that glucosamine is structurally related to glucose. Laflamme et al. (2010) specifically investigated this in a prospective crossover study of 12 healthy dogs receiving oral glucosamine-chondroitin for 21 days and found no significant change in serum fructosamine concentration — confirming that short-term glucosamine supplementation does not affect glycaemic control or induce diabetes mellitus in healthy dogs.¹⁵ However, diabetic dogs or those with insulin resistance should be monitored, and veterinary advice sought before starting supplementation.

Glucosamine HCl is not known to have significant drug interactions at supplement-level doses. It can be used alongside NSAIDs, and some veterinary practitioners recommend this combination to support a gradual reduction in NSAID dosage as glucosamine’s cumulative benefits develop. As with any supplement, consultation with a veterinarian is advisable before beginning use, particularly in dogs with pre-existing conditions.

How to Give Glucosamine HCl to Your Dog

Dosage Guidelines

Veterinary dosing recommendations for glucosamine HCl typically range from 20–25 mg/kg body weight per day, though no definitive therapeutic dose has been established in the canine literature.⁴ Many clinical studies have used higher doses, and the optimal dose likely varies by individual dog, severity of joint disease, and concurrent supplementation.

Dog Weight	Suggested Daily Glucosamine HCl	Bounce Chewies/Day
Small (up to 10kg)	200–250mg	1 chewy
Medium (10–25kg)	250–500mg	1–2 chewies
Large (25–40kg)	500–750mg	2–3 chewies
Giant (40kg+)	750–1000mg	3–4 chewies

Bounce provides 240mg glucosamine HCl per chewy. Follow the dosage guidance on the product label. These guidelines are for general information and do not replace veterinary advice.

Practical Considerations

Onset of effect: Glucosamine is not a fast-acting analgesic. The McCarthy et al. (2007) canine trial demonstrated significant clinical improvements at day 70, with onset slower than the NSAID comparator.¹ This reflects glucosamine’s mechanism as a substrate for gradual cartilage repair rather than an acute anti-inflammatory. Owners should commit to at least 8–12 weeks of consistent daily supplementation before evaluating efficacy.

HCl versus sulphate: Glucosamine HCl provides a higher percentage of free glucosamine per gram than glucosamine sulphate.⁴ Both forms dissociate in the stomach to release identical free glucosamine.⁴ Glucosamine HCl is also more chemically stable, requires no sodium or potassium chloride stabilisers, and is the form most commonly used in veterinary products.⁴

Bioavailability: Approximately 12% of oral glucosamine HCl is absorbed systemically in dogs, with rapid absorption (peak plasma concentration at approximately 1.5 hours).⁶ While this bioavailability may appear modest, it is sufficient to achieve therapeutically relevant concentrations in synovial fluid and cartilage, and glucosamine demonstrates a tropism (preferential distribution) for joint tissues.⁶

Vegan-sourced glucosamine: Traditional glucosamine is derived from shellfish chitin. Bonza uses vegan-sourced glucosamine HCl produced by fungal fermentation, making it suitable for plant-based formulations without compromising chemical identity or bioactivity.

Storage and stability: Glucosamine HCl is stable in powder and chewy supplement forms at room temperature. Store in a cool, dry place away from direct sunlight and moisture.

Concurrent supplements: Glucosamine works synergistically with chondroitin sulphate, MSM, hyaluronic acid, and omega-3 fatty acids. Proteomics research confirms that the combination of glucosamine and chondroitin produces synergistic effects on chondrocyte protein expression that exceed either compound alone, particularly in modulating cartilage extracellular matrix metabolism.¹⁶

Long-term use: There is no evidence of adverse effects from long-term oral glucosamine supplementation. Given the progressive, chronic nature of osteoarthritis, ongoing daily supplementation is generally appropriate for dogs with established joint conditions or those at increased risk due to breed, size, age, or activity level.

Frequently Asked Questions

Related Reading

• Hyaluronic Acid for Dogs: Joint Mobility & Inflammation Support
• Avocado-Soybean Unsaponifiables (ASU) for Dogs: Joint Protection & Mobility Support
• The Gut-Joint Axis: How Your Dog’s Gut Health Affects Their Joints
• The Gut Microbiome: Your Dog’s Hidden Health Command Centre
• Best Prebiotics for Dogs
• Best Probiotics for Dogs: A Canine Nutritionist’s Guide

References

1. McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. The Veterinary Journal. 2007;174(1):54–61. doi: 10.1016/j.tvjl.2006.02.015. PMID: 16647870.
2. Largo R, Alvarez-Soria MA, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage. 2003;11(4):290–298. doi: 10.1016/S1063-4584(03)00028-1. PMID: 12681956.
3. Moon JM, Finnegan P, Engelen MPKJ, Deutz NEP, Aguree S, Millward H, Shaimerdenova M, Jäger R, Purpura M, Kerksick CM. Impact of glucosamine supplementation on gut health. Nutrients. 2021;13(7):2180. doi: 10.3390/nu13072180. PMID: 34202877. PMC: PMC8308242.
4. Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: a review. Open Veterinary Journal. 2017;7(1):36–49. doi: 10.4314/ovj.v7i1.6. PMID: 28331832. PMC: PMC5356289.
5. Imagawa K, de Andrés MC, Hashimoto K, Pitt D, Itoi E, Goldring MB, Roach HI, Oreffo ROC. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes — implications for osteoarthritis. Biochemical and Biophysical Research Communications. 2011;405(3):362–367. doi: 10.1016/j.bbrc.2011.01.007. PMID: 21219853. PMC: PMC3937866.
6. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharmaceutics & Drug Disposition. 2002;23(6):217–225. doi: 10.1002/bdd.315. PMID: 12214321.
7. Navarro SL, Levy L, Curtis KR, Lampe JW, Hullar MAJ. Modulation of gut microbiota by glucosamine and chondroitin in a randomized, double-blind pilot trial in humans. Microorganisms. 2019;7(12):610. doi: 10.3390/microorganisms7120610. PMID: 31769443. PMC: PMC6955791.
8. Wenz W, Hornung C, Cramer C, Schroeder M, Hoffmann M. Effect of glucosamine sulfate on osteoarthritis in the cruciate-deficient canine model of osteoarthritis. Cartilage. 2017;8(2):173–179. doi: 10.1177/1947603516638898. PMID: 28345412. PMC: PMC5358821.
9. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. International Journal of Rheumatology. 2011;2011:969012. doi: 10.1155/2011/969012. PMID: 21826146. PMC: PMC3150191.
10. Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1β. Arthritis Research & Therapy. 2006;8(6):R173. doi: 10.1186/ar2082. PMID: 17109748. PMC: PMC1794523.
11. Collaresi S, Brighenti V, Ferraro L, et al. Efficacy of a dietary supplement in dogs with osteoarthritis: a randomized placebo-controlled, double-blind clinical trial. PLoS ONE. 2022;17(2):e0263971. doi: 10.1371/journal.pone.0263971. PMID: 35171962.
12. Kampa N, Kaenkangploo D, Jitpean S, et al. Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis. Frontiers in Veterinary Science. 2023;10:1033188. doi: 10.3389/fvets.2023.1033188. PMID: 36816197. PMC: PMC9929184.
13. Shmagel A, Demmer R, Knights D, Butler M, Langsetmo L, Lane NE, Ensrud K. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. Nutrients. 2019;11(2):294. doi: 10.3390/nu11020294. PMID: 30704054. PMC: PMC6412843.
14. Zhu X, Cai J, Wang Y, Liu X, Chen X, Wang H, Wu Z, Bao W, Fan H, Wu J. Glucosamine ameliorates symptoms of high-fat diet-fed mice by reversing imbalanced gut microbiota. Frontiers in Pharmacology. 2021;12:694107. doi: 10.3389/fphar.2021.694107. PMID: 34149431. PMC: PMC8213355.
15. Laflamme DP, Xu H, Cupp CJ, Kerr WW, Ramadan Z, Long GM. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. Journal of the American Veterinary Medical Association. 2010;236(2):183–186. doi: 10.2460/javma.236.2.183. PMID: 20074008.
16. Calamia V, Lourido L, Fernández-Puente P, Mateos J, Rocha B, Montell E, Vergés J, Ruiz-Romero C, Blanco FJ. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Scientific Reports. 2014;4:5069. doi: 10.1038/srep05069. PMID: 24912672. PMC: PMC4050385.

---

Editorial Information

Field	Detail
Published	February 2026
Last Updated	February 2026 — Original publication
Reviewed by	Glendon Lloyd, Dip. Canine Nutrition, Dip. Canine Nutrigenomics (Distinction)
Next Review	August 2026
Author	Glendon Lloyd
Disclaimer	This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.

---

About the Author

Glendon Lloyd | Dip. Canine Nutrition (Dist.) | Dip. Canine Nutrigenomics (Dist.) Founder, Bonza

Glendon Lloyd is a canine nutrition researcher specialising in nutrigenomics, gut microbiome science, and the therapeutic application of plant-based bioactive compounds. His work focuses on the gut-organ axes and their role in immune function, inflammatory conditions, and healthspan optimisation. He reviews 5–6 peer-reviewed studies weekly to inform evidence-based formulation and clinical guidance.

→ Full author credentials and research background